Pharmaxis (ASX:PXS) commences enrolment for myelofibrosis clinical trial

  • February 22, 2021 03:01 PM AEDT
  • Team Kalkine
    Team Kalkine
    Team Kalkine
    16964 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

Australian pharmaceutical research player Pharmaxis Ltd (ASX:PXS) updated the market that the Company has enrolled the first patient for the clinical study of its lead compound PXS-5505 to determine the safety in patients with myelofibrosis. 

Here are some key highlights of the study-

  • Pharmaxis disclosed that the first patient for the trial to study a potential new treatment for bone marrow cancer myelofibrosis has been enrolled.
  • The primary endpoint of the clinical study is to evaluate the safety of PXS-5505 in patients having myelofibrosis.
  • PXS-5505 is the lead asset in the drug discovery pipeline of Pharmaxis.
  • Pharmaxis has completed site initiation at several hospitals in Australia and South Korea.
  • Pharmaxis updated the market that the clinical investigation sites in other countries, including the US, will be added for the dose-expansion phase.

DETAILED DISCUSSION AT: Here’s the latest development on Pharmaxis’ (ASX:PXS) cancer treatment

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK